Kiniksa Pharmaceuticals International, plc
78.52USD
+1.4300 (+1.85%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 214 | 202 | 181 | 157 | 138 | 123 | 112 | 109 |
| Cost of Revenue | 21 | 21 | 20 | 19 | 18 | 18 | 20 | 12 |
| Gross Profit | 193 | 181 | 161 | 138 | 120 | 105 | 92 | 96 |
| Operating Income | 29 | 20 | 24 | 20 | 13 | -19 | -10 | -0 |
| Net Income | 23 | 14 | 18 | 18 | 9 | -9 | -13 | -4 |
| EPS (Diluted) | $0.27 | $0.18 | $0.23 | $0.23 | $0.11 | $-0.12 | $-0.18 | $-0.06 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)